Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
N Engl J Med
; 383(26): 2526-2537, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369355
3.
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Haematologica
; 107(5): 1086-1094, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162178
4.
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Br J Haematol
; 192(6): 1015-1019, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32436212
5.
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(5): 649-662, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948276
6.
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
Br J Haematol
; 176(4): 573-582, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28032335
7.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
N Engl J Med
; 371(3): 213-23, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881631
8.
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
Br J Haematol
; 175(4): 668-672, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27477167
9.
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Haematologica
; 101(2): 235-40, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26611473
10.
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
Haematologica
; 106(12): 3240-3244, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551506
11.
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Lancet Oncol
; 15(4): 424-35, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24602760
12.
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Lancet
; 381(9880): 1817-26, 2013 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23615461
13.
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
Blood
; 120(2): 291-4, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22645182
14.
Lymphoid blast crisis after prolonged treatment-free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de-escalation during the COVID-19 pandemic.
EJHaem
; 3(1): 215-217, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35846212
15.
A case of Stage IA classical Hodgkin lymphoma with FDG-avid tonsils.
Br J Haematol
; 173(2): 178, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26872151
16.
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Br J Haematol
; 152(5): 570-8, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21231927
17.
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
J Hematol Oncol
; 14(1): 133, 2021 08 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454540
18.
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.
Br J Haematol
; 164(1): 39-52, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24117159
19.
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Lancet Haematol
; 6(7): e375-e383, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31201085
20.
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Lancet Haematol
; 6(5): e276-e284, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036317